Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of nebivolol in preparation of MCR-1 enzyme inhibitor

A technology of MCR-1 and inhibitors, which is applied in the direction of resistance to vector-borne diseases, medical preparations containing active ingredients, antibacterial drugs, etc., and can solve problems such as nebivolol not seen

Inactive Publication Date: 2021-01-19
ACADEMY OF MILITARY MEDICAL SCI
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But up to now, there are no relevant reports on nebivolol in the preparation of MCR-1 inhibitors at home and abroad

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of nebivolol in preparation of MCR-1 enzyme inhibitor
  • Application of nebivolol in preparation of MCR-1 enzyme inhibitor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0013] Example 1 Effect of Nebivolol on Bacterial Growth

[0014] 1. Sample treatment: Dissolve nebivolol in DMSO, make a suitable initial concentration with culture medium, and then dilute with culture medium 2 times, a total of 4 dilutions.

[0015] 2. Bacterial suspension preparation: resuscitate BL21(DE3) and BL21(DE3) expressing mcr-1 on LB plates, pick single colonies respectively and enrich them in MH medium.

[0016] 3. Test method: put 1×10 6 c.f.u.ml -1 The bacterial solution was inoculated in a 96-well culture plate, 50 μL per well, and then 50 μL of nebivolol solution was added. The final concentration of the bacterial solution was 5×10 5 c.f.u.ml -1 , the final concentrations of nebivolol were 62.5 μM, 125 μM, 250 μM and 500 μM. At the same time, set the control, which is the same volume of control wells that only add bacterial solution. Incubate at 37°C for 16 hours, and observe with the naked eye under a dark background whether there is bacterial growth in...

Embodiment 2

[0018] Example 2 Nebivolol combined with 2 μg·mL -1 Antibacterial activity of colistin against BL21(DE3) expressing mcr-1

[0019] 1. Sample treatment: Dissolve nebivolol in DMSO, make a suitable initial concentration with culture medium, and then dilute with culture medium 2 times, a total of 4 dilutions.

[0020] 2. Bacterial suspension preparation: resuscitate BL21(DE3) expressing mcr-1 on LB plates, pick single colonies and multiply them in MH medium.

[0021] 3. Test method: put 1×10 6 c.f.u.ml -1 The bacterial solution was inoculated in a 96-well culture plate, 50 μL per well, 25 μL of nebivolol solution was added to the corresponding well, and then 25 μL of colistin solution was added. The final concentration of the bacterial solution was 5×10 5 c.f.u.ml -1 , the final concentration of nebivolol was 12.5 μM, 25 μM, 50 μM, 100 μM, and the final concentration of colistin was 2 μg·mL -1 . At the same time, a control is set, which is the control wells only added with...

Embodiment 3

[0023] Example 3 Inhibitory effect of nebivolol on MCR-1 protein activity

[0024] 1. Construction of the MCR-1 protein expression plasmid: the mcr-1 gene was inserted into the plasmid pET21a(+) through the restriction site Nde1 / Xho1, and whether the recombinant plasmid was successfully constructed was verified by sequencing.

[0025] 2. Expression of MCR-1 protein: the recombinant plasmid pET21a(+)-mcr-1 was transfected into BL21(DE3) for bacterial culture. Pick a single colony from the agar plate and inoculate it in a medium containing 100 μg mL -1 Ampicillin was cultured overnight at 37°C in LB medium. The expanded bacteria solution was inoculated in LB culture medium at a ratio of 1:100, cultivated at 37°C until the OD600 reached 0.6, added 0.5mMIPTG, and cultivated overnight at 18°C. Centrifuge at low speed to take the precipitate, wash with 1×PBS, and store at -80°C.

[0026] 3. Purification of MCR-1 protein: Take the above-mentioned bacterial cell precipitate, resusp...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of nebivolol in preparation of an MCR-1 enzyme inhibitor. The nebivolol is verified to be capable of restoring the antibacterial activity of polymyxin to mcr-1 positive escherichia coli through a trace broth dilution method. Furthermore, the nebivolol is verified to be capable of inhibiting the transfer activity of MCR-1 protein to phosphoethanolamine through athin layer chromatography. Therefore, the nebivolol and the polymyxin are combined for application, an experimental basis is provided for a new strategy for treating mcr-1 positive drug-resistant bacteria, and the nebivolol has important research value for solving the problem of drug resistance.

Description

technical field [0001] The invention discloses a new application of nebivolol, relates to the application of nebivolol in the preparation of MCR-1 enzyme inhibitors, and belongs to the technical field of medical pharmacy. Background technique [0002] At present, the problem of bacterial drug resistance is a serious threat to human health. Globally, the number of deaths caused by multi-drug resistant bacterial infections is as high as 700,000 every year. Due to the lack of development of new antibiotics, polymyxin, an ancient antibiotic, has been reapplied in clinic and is regarded as the last line of drug defense against infections caused by certain drug-resistant bacteria. [0003] Polymyxin is isolated from the culture fluid of Paenibacillus polymyxa, and is divided into five types: A, B, C, D, and E. Among them, polymyxin B and polymyxin E (myxomyces prime) for clinical use. In the past, it was believed that polymyxin resistance was mainly mediated by chromosomal mutat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/353A61P31/04
CPCA61K31/353A61P31/04Y02A50/30
Inventor 李松肖军海兰秀娟闫海涛钟武郑志兵王晓奎谢云德曹瑞源李行舟
Owner ACADEMY OF MILITARY MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com